These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31670210)

  • 1. Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis.
    Erdal JL; Kopp TI; Blinkenberg M; Petersen T; Sørensen PS; Magyari M
    Mult Scler Relat Disord; 2020 Jan; 37():101431. PubMed ID: 31670210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis.
    Harding K; Williams O; Willis M; Hrastelj J; Rimmer A; Joseph F; Tomassini V; Wardle M; Pickersgill T; Robertson N; Tallantyre E
    JAMA Neurol; 2019 May; 76(5):536-541. PubMed ID: 30776055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis.
    Huisman E; Papadimitropoulou K; Jarrett J; Bending M; Firth Z; Allen F; Adlard N
    BMJ Open; 2017 Mar; 7(3):e013430. PubMed ID: 28283486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data.
    Gontika M; Skarlis C; Markoglou N; Evangelopoulos ME; Velonakis G; Chrousos GP; Dalakas M; Stefanis L; Anagnostouli M
    Neurol Sci; 2022 Apr; 43(4):2641-2649. PubMed ID: 34596776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
    Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
    Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS?
    Fernández Ó
    Mult Scler Relat Disord; 2017 Oct; 17():75-83. PubMed ID: 29055479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
    Koch-Henriksen N; Magyari M; Sellebjerg F; Soelberg Sørensen P
    Mult Scler; 2017 Feb; 23(2):234-241. PubMed ID: 27055806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.
    Chappuis M; Rousseau C; Bajeux E; Wiertlewski S; Laplaud D; Le Page E; Michel L; Edan G; Kerbrat A
    J Neurol; 2023 Jan; 270(1):413-422. PubMed ID: 36121558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
    Chen J; Taylor BV; Blizzard L; Simpson S; Palmer AJ; van der Mei IAF
    J Neurol Neurosurg Psychiatry; 2018 Nov; 89(11):1200-1207. PubMed ID: 29921609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Lahoz R; Reynolds T; Korn JR
    Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
    Barbin L; Rousseau C; Jousset N; Casey R; Debouverie M; Vukusic S; De Sèze J; Brassat D; Wiertlewski S; Brochet B; Pelletier J; Vermersch P; Edan G; Lebrun-Frenay C; Clavelou P; Thouvenot E; Camdessanché JP; Tourbah A; Stankoff B; Al Khedr A; Cabre P; Papeix C; Berger E; Heinzlef O; Debroucker T; Moreau T; Gout O; Bourre B; Créange A; Labauge P; Magy L; Defer G; Foucher Y; Laplaud DA;
    Neurology; 2016 Feb; 86(8):771-8. PubMed ID: 26826205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of treatment outcome in patients with paediatric onset multiple sclerosis.
    Kopp TI; Blinkenberg M; Chalmer TA; Petersen T; Ravnborg MH; Soelberg Sørensen P; Magyari M
    Mult Scler; 2020 Jul; 26(8):964-975. PubMed ID: 31081451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment.
    Bedri SK; Nilsson OB; Fink K; Månberg A; Hamsten C; Ayoglu B; Manouchehrinia A; Nilsson P; Olsson T; Hillert J; Grönlund H; Glaser A
    PLoS One; 2019; 14(5):e0217208. PubMed ID: 31141529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melanoma during fingolimod treatment for multiple sclerosis.
    Velter C; Thomas M; Cavalcanti A; Bastien M; Chochon F; Lubetzki C; Routier E; Robert C
    Eur J Cancer; 2019 May; 113():75-77. PubMed ID: 30986706
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
    Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis treatment effects on plasma cytokine receptor levels.
    Bedri SK; Fink K; Manouchehrinia A; Lundström W; Kockum I; Olsson T; Hillert J; Glaser A
    Clin Immunol; 2018 Feb; 187():15-25. PubMed ID: 28941836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.